P30419 (NMT1_HUMAN) Homo sapiens (Human)

Glycylpeptide N-tetradecanoyltransferase 1 UniProtKBInterProSTRINGInteractive Modelling

496 aa; Sequence (Fasta) ; (Isoform 2); 4 identical sequences: Pongo abelii: A0A2J8UYT3; Pan troglodytes: H2QD84, A0A6D2WXT8; Pan paniscus: A0A2R9BQM1

Available Structures

43 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
HsNMT1 in complex with CoA and Myristoylated-GCSVSKKK octapeptide Heteromer
O81223;
104-496
100COA;GOL;MYR;
HsNMT1 in complex with CoA and Myristoylated-GGCFSKPK octapeptide Heteromer
Q96NN9;
104-496
100COA;GOL;CL;MYR;
HsNMT1 in complex with both MyrCoA and HCPA substrate peptide GKQNSKLR Heteromer
P84074;
105-496
100GOL;MYA;
DeltaC3 C-terminal truncation of HsNMT1 in complex with MyrCoA and GDCFSKPR substrates Heteromer
Q96NN9;
102-493
100MYA;GOL;CL;
HsNMT1 in complex with both MyrCoA and Acetylated-GKSFSKPR peptide reveals N-terminal Lysine Myrist… Heteromer
Q96NN9;
105-496
100GOL;COA;MYR;
HsNMT1 in complex with both MyrCoA and Acetylated-GNCFSKPR substrates Heteromer
Q96NN9;
105-496
100.0MYA;CL;GOL;
HsNMT1 in complex with both MyrCoA and GNCFSKRRAA substrates Heteromer
Q96NN9;
105-496
100COA;GOL;CL;MYR;
DeltaC2 C-terminal truncation of HsNMT1 in complex with MyrCoA and GNCFSKPR substrates Heteromer
Q96NN9;
104-494
100.0GOL;MYA;
C-terminal HsNMT1 deltaC3 truncation in complex with both MyrCoA and GNCFSKPR substrates Heteromer
Q96NN9;
104-493
100.0GOL;MYA;
HsNMT1 in complex with CoA and Myristoylated-GKSNSKLK octapeptide Heteromer
P62166;
115-496
100.0GOL;CL;MYR;
Structure of Human NMT1 with products CoA and myristoyl-lysine peptide with acetylated N-terminus Heteromer
P62330;
116-496
100.0COA;GOL;MYR;
Crystal structure of human N-myristoyltransferase 1 fragment (residues 109-496) bound to diacylated… Heteromer
P62330;
145-496
1004PS;MYR;6NA;
Mutant of Human N-myristoyltransferase with bound myristoyl-CoAhomo-4-mer115-496
97.91MYA;MG;GOL;
HsNMT1 in complex with both MyrCoA and GNCFSKAR inhibitor peptidehomo-2-mer105-496
100.0COA;GOL;CL;MYR;
HsNMT1 in complex with both MyrCoA and ACE-G-(L-ORN)SFSKPRmonomer103-496
100GOL;MYA;
HsNMT1 in complex with both MyrCoA and GNCFSKPR inhibitor peptidemonomer104-496
100COA;CL;MG;MYR;
HsNMT1 in complex with both MyrCoA and Ac-D-ORN-SFSKPR inhibitor peptidemonomer104-496
100GOL;CL;MYA;
HsNMT1 in complex with both MyrCoA and GNCFSKPRVPTK inhibitor peptidemonomer104-496
100COA;GOL;CL;MYR;
HsNMT1 in complex with both MyrCoA and peptide AKSFSKPRmonomer104-496
100GOL;MYA;
HsNMT1 in complex with both MyrCoA and GNCFSKPR(NH2) inhibitor peptidemonomer104-496
100COA;GOL;CL;MYR;
HsNMT1 in complex with both MyrCoA and N-acetylated KSFSKPR peptidemonomer105-496
100GOL;COA;MYA;MYR;
HsNMT1 in complex with both MyrCoA and GNLLSKFR peptidemonomer105-496
100COA;GOL;CL;MG;MYR;
HsNMT1 in complex with CoA and acetylated-NCFSKPK peptidemonomer105-496
100MYA;GOL;CL;
HsNMT1 in complex with both MyrCoA and (DAB)SFSKPR inhibitor peptidemonomer106-496
100.0MYA;GOL;CL;
HsNMT1 in complex with both CoA and Myr-ANCFSKPR peptidemonomer106-496
100COA;GOL;MYR;
HsNMT1 in complex with both MyrCoA and peptide GGKSFSKPRmonomer106-496
100.0GOL;MYA;
HsNMT1 in complex with both MyrCoA and peptide N-Methylated-GNCFSKPRmonomer106-496
100MYA;
Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-917monomer115-496
100MYA;PO4;9M2;MG;GOL;DMS;
Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoAmonomer115-496
100.0MYA;
Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-1031monomer115-496
100MYA;PO4;MG;9M8;
Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA and inhibitor DDD…monomer115-496
100MYA;X55;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA co-factormonomer115-496
100MYA;MG;CIT;GOL;
Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA and inhibitor DDD…monomer115-496
100MYA;096;
Crystal Structure of human type-I N-myristoyltransferase with bound myristoyl-CoA and inhibitor DDD…monomer115-496
100MYA;646;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and IMP-1088 inhibitor boundmonomer115-496
100MYA;MG;GOL;KFK;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor boundmonomer115-496
100BXN;MYA;MG;GOL;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor boundmonomer115-496
100EBK;MYA;MG;GOL;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor boundmonomer115-496
100MYA;646;MG;CIT;GOL;CL;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and peptide boundmonomer115-496
100.0GOL;MYA;GLY;SER;ASN;LYS;PRO;MYR;COA;
N-myristoyltransferase 1 (NMT) bound to myristoyl-CoAmonomer115-496
100.0MYA;CIT;
Human N-myristoyltransferase 1 (MNT1) with Myristoyl-CoA analogue X10 boundmonomer115-496
100.0GOL;94Q;MG;
Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and inhibitor boundmonomer116-496
100.031A;MYA;MG;GOL;
Crystal structure of human myristoyl-CoA:protein N-myristoyltransferase.monomer155-496
99.71SO4;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6qrm.2.Amonomer0.91105-496
100.00

1 SWISS-MODEL model built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 28q26.1.Amonomer0.9124-416
GLY;COA;MG;100.00